Lepu Biopharma Co. Ltd. Class H (2157) Stock Statistics & Valuation Metrics

Lepu Biopharma Co. Ltd. Class H has a market cap or net worth of HK$9.96B. The enterprise value is HK$10.67B.

Lepu Biopharma Co. Ltd. Class H has 1,656,346,400 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lepu Biopharma Co. Ltd. Class H’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -21.47%.

The current PE Ratio of Lepu Biopharma Co. Ltd. Class H is -10.11. Lepu Biopharma Co. Ltd. Class H’s PEG ratio is 0.50.

In the last 12 months, Lepu Biopharma Co. Ltd. Class H had revenue of 367.79M and earned -411.38M in profits. Earnings per share was -0.24.

In the last 12 months, operating cash flow was -115.16M and capital expenditures 0.00, giving a free cash flow of -127.32M billion.

Lepu Biopharma Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Lepu Biopharma Co. Ltd. Class H upcoming earnings date is Aug 21, 2025, TBA Not Confirmed.

Lepu Biopharma Co. Ltd. Class H as a current ratio of 0.62, with Debt / Equity ratio of 76.64%

In the past 12 months, Lepu Biopharma Co. Ltd. Class H has paid 0.00 in taxes.

Lepu Biopharma Co. Ltd. Class H EV to EBITDA ratio is -14.77, with an EV/FCF ratio of 0.00.

Lepu Biopharma Co. Ltd. Class H has HK$464.91M in cash and marketable securities with ¥850.16M in debt, giving a net cash position of HK$385.25M billion.

Gross margin is 87.12%, with operating margin of -106.25%, and net profit margin of -111.85%.

The average price target for Lepu Biopharma Co. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―